Physician profile
Michelle Ecker
NPI 1942295415
$3,568.59
in general payments reported to CMS, 2019-2025
24 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $123 · 2021: $538 · 2022: $406 · 2023: $831 · 2024: $818 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $915.33 | 2020-2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $495.67 | 2023-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $396.61 | 2022-2024 | Farxiga |
| Abbott Laboratories | $333.86 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $213.09 | 2024-2025 | |
| Medtronic Vascular, INC. | $166.36 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $134.82 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $131.11 | 2022-2023 | Verquvo |
| Medtronic, INC. | $124.71 | 2021 | |
| Novo Nordisk INC | $119.08 | 2024-2025 | Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $103.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $60.87 | 2024 | Voquezna |
| Lilly USA, LLC | $59.71 | 2024-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $42.13 | 2024-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.98 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $29.50 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.00 | 2024 | Rexulti |
| Janssen Biotech, INC. | $17.79 | 2019 | |
| Inspire Medical Systems, INC. | $16.01 | 2024 | Inspire |
| Amgen INC. | $15.13 | 2024 | Otezla, Repatha |
| Linus Health, INC. | $14.95 | 2024 | Core Cognitive Evaluation |
| Currax Pharmaceuticals LLC | $13.92 | 2025 | Contrave |
| Astellas Pharma US INC | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.